MILWAUKEE, Jan. 11, 2024 /PRNewswire/ -- Ademi LLP is investigating Transphorm (Nasdaq: TGAN) for possible breaches of fiduciary duty and other violations of law in its transaction with Renesas.

AdemiLogo (PRNewsfoto/Ademi LLP)

Click here to learn how to join the https://www.ademilaw.com/case/transphorm-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Transphorm stockholders will receive only $5.10 per share, valuing Transphorm at approximately $339 million. The transaction agreement unreasonably limits competing transactions for Transphorm by imposing a significant penalty if Transphorm accepts a competing bid. Transphorm insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Transphorm's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Transphorm common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/transphorm-inc.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-transphorm-inc-has-obtained-a-fair-price-in-its-transaction-with-renesas-302032611.html

SOURCE Ademi LLP